Non-Small Cell Lung Cancer - Metastatic

1st line

Recurrent or Metastatic (IIIB, IV)

Correlatives

No Trials Currently Available

Squamous

Non-squamous

IRB# 11851
GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) In Combination With Carboplatin+Paclitaxel Or Atezolizumab In Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel In Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

IRB# 18114
IRB# 11845
GO29431: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) Compared with a Platinum Agent (Cisplatin or Carboplatin) in Combination with Either Pemetrexed or Gemcitabine for PD-L1-Selected Chemotherapy Naive Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

IRB# 18114
IRB# 11845

2nd/3rd Line

IRB# 11851
GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Anti-Pd-L1 Antibody) In Combination With Carboplatin+Paclitaxel Or Atezolizumab In Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel In Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer

IRB# 11046
Lung-MAP: Study involving multiple drugs

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold